The Latest Breaking News from BMY

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy is likely to enter a recession, making pharma stocks attractive investment options. Therefore, investors could look to…

With the Fed’s measures to counter inflation causing the collateral damage of asset price deflation, it could be wise to load up on Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), and DoubleDown Interactive (DDI), available at attractive valuations to capture future upside potential while limiting downside risks. Continue reading….

Recent rhetoric from the Federal Reserve, the collapse of the Silicon Valley Bank, and strong economic data have now resulted in an extremely volatile market backdrop. Against this, adding fundamentally sound stocks Bristol-Myers Squibb (BMY), General Motors (GM), McKesson Corp. (MCK), Cardinal Health (CAH), and American Vanguard (AVD) to your…

Although the stock market remains highly volatile, investing for the long term can never be timed perfectly. I believe buying fundamentally strong biopharmaceutical major Bristol-Myers Squibb (BMY) now for the long term could be wise, given the solid prospects of its new drug launches. Read more….

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

The stock market is expected to remain volatile in the near term as investors remain anxious about the Fed’s actions. Amid high recession worries, fundamentally strong healthcare stocks, Pfizer (PFE), Bristol-Myers Squibb (BMY), Amgen (AMGN), and Elevance Health (ELV), which have the potential to withstand any market downturns, could be…

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…

The pharmaceutical industry is evolving with personalized medicines and the rapid adoption of RPM technology, which should boost growth. Moreover, with a recession lurking, fundamentally strong pharma stocks AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) might be ideal buys. However, SNDL (SNDL) might be best avoided. Keep reading to know why.

The stock market’s outlook seems choppy as investors weigh data on the state of the economy, labor market, and future rate increases by the Federal Reserve. With more volatility expected for the near term, one should consider safeguarding their portfolios with fundamentally sound stocks Coca-Cola (KO), Bristol-Myers Squibb (BMY), and…

Leading pharma company Bristol-Myers Squibb’s (BMY) fiscal year 2022 revenue and EPS were in line with analysts’ estimates. While BMY continues to advance its innovative portfolio and pipeline, is it a good dividend stock to pick up right now? Read more to find out.

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…